Owning a dog may boost teens’ social skills and mental health through the microbiota

Some bacteria common in dog owners, particularly Streptococcus strains, were linked to fewer behavioral and attention problems.

Postbiotics: the story, the evidences, the ingredient

How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.

Gut microbiota, intestinal barrier, and sepsis: from dysbiosis to probiotics—what preclinical evidence suggests

Francesco Franceschi from Policlinico Universitario A. Gemelli IRCCS (Roma) focuses on bacterial translocation across a compromised intestinal barrier as a plausible pathway contributing to sepsis.

Antibiotic-producing gut microbes might raise infection risk

Lantibiotic-producing gut bacteria can prolong gut imbalance and increase susceptibility to dangerous infections after antibiotics.

Toxin produced by gut bacteria may drive ulcerative colitis

MTB and aerolysin drive gut inflammation in ulcerative colitis.

Microbiome testing for post-infectious IBS: a pilot “microbe-informed” approach presented in Brussels

William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.

Nutrient competition may predict how gut microbes respond to drugs

Nutrient competition provides a predictive framework to anticipate and potentially mitigate drug side effects on the gut microbiota.

Gut bacteria and leucine may determine who benefits from exercise 

The interaction between gut microbes, the amino acid leucine and sIL-6R determines a person’s responsiveness to exercise.

Pharmabiotics Conference 2026: where microbiome development meets regulation

Camille Bello, Communication and Membership Manager at Pharmabiotics Research Institute, underscores the conference’s regulatory focus and PRI’s role in guiding microbiome innovations through complex approval pathways.

Pharmabiotics Conference 2026: three days in Brussels on microbiome biomarkers, one health, and a shifting regulatory landscape

Celine Druart, Executive Director at Pharmabiotic Research Institute, discusses the 10th Pharmabiotics Conference in Brussels, from microbiome biomarkers and One Health to key regulatory developments shaping live biotherapeutic products.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top